GlassScriptPhysician profile
Delaney S Hales
NPI 1790135960
$4,452.65
in general payments reported to CMS, 2019-2025
25 companies · $873 in 2025
The $873 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $672 · 2022: $976 · 2023: $1,051 · 2024: $880 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,613.35 |
| Education | $191.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,195.00 | 2021-2025 | |
| Genzyme Corporation | $624.70 | 2022-2025 | |
| Janssen Biotech, INC. | $411.07 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $407.30 | 2021-2025 | Dupixent, Libtayo |
| Sanofi-Aventis U.S. LLC | $261.99 | 2021-2023 | |
| Pfizer INC. | $188.23 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $147.34 | 2022-2024 | Sotyktu |
| Incyte Corporation | $126.38 | 2021-2025 | Opzelura |
| Amgen INC. | $120.43 | 2022-2024 | Otezla |
| Lilly USA, LLC | $116.73 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $112.47 | 2021-2024 | Bimzelx |
| Leo Pharma INC. | $92.71 | 2021-2025 | Anzupgo, Adbry |
| Galderma Laboratories, L.P. | $89.70 | 2021-2025 | Oracea, Aklief, Nemluvio |
| Organogenesis INC. | $89.39 | 2021-2023 | Puraply |
| Arcutis Biotherapeutics, INC. | $78.56 | 2023-2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $77.83 | 2023-2025 | |
| Dermavant Sciences, INC. | $61.81 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2023-2024 | Spevigo |
| Sun Pharmaceutical Industries INC. | $42.69 | 2023 | Winlevi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.49 | 2025 | Jublia |
| Almirall LLC | $37.93 | 2024 | Klisyri |
| Mayne Pharma Commercial LLC | $30.89 | 2025 | |
| Organon LLC | $25.03 | 2025 | |
| Biofrontera INC. | $16.02 | 2022 | |
| Botanix Sb INC | $15.70 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaney Hales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.